Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-02-27-Speech-3-106"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-02-27"^^xsd:date2
dcterms:Is Part Of	lp_eu:Barcelona European Council2
dcterms:Language	"el"^^xsd:language2
lpv:document identification number	"en.20020227.6.3-106"2
lpv:hasSubsequent	lp_eu:2002-02-27-Speech-3-1072
lpv:speaker	lp:Antonios Trakatellis2
lpv:spokenAs	substitute; Temporary committee on foot and mouth disease (2002-01-17--2002-12-17)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3 member; Delegation for relations with Israel (2002-02-07--2004-07-19)3 member_of_the_bureau; EPP-ED (2000-04-10--2004-07-19)3 substitute; Committee on Foreign Affairs, Human Rights, Common Security and Defence Policy (2002-01-17--2004-07-19)3 unknown; Nea Dimokratia (1999-07-20--2004-07-19)3
lpv:translated text	"Mr President, a great deal has been said already. I have just two comments to make. The first concerns the strategy for sustainable development in the run up to the Barcelona Summit, which puts flesh on the bones of the endeavour started in Gothenburg last year, when the environmental dimension was woven into economic development and social cohesion, successfully in my view. The common objective of these endeavours is to put the European Union's long-term, global strategy on sustainable development into practice. Biotechnology is an important sector today – and will be even more important tomorrow – and we must not overlook that aspect of it which can play an important part in sustainable development. This point is covered in Amendment No 27 proposed by my group. If used with care, biotechnological applications, and genetically-modified organisms in particular, can make a positive contribution both to the economy and trade and to environmental protection, for numerous reasons which there is no need to reiterate. At the same time, if we are to establish consumer confidence, we need to pay attention to concerns on this count and the call for analytical control methods, as well as markers and tracers, to be applied to genetically modified organisms is a legitimate one. It will guarantee compliance with the principles of safety, responsibility and proper information and, at the same time, create conditions of healthy competition in a highly promising sector. My second comment concerns the Commission communication on the action plan on mobility. The Commission proposal for a social security card is lacking in substance. Why? Because it does not create a European area of health which meets the demands of European citizens; all it does is simplify bureaucratic procedures. Unless the card includes details and medical data, naturally with the interested party's consent, which can be used in the other Member States, it will do nothing to improve present medical coverage at European level. Naturally, what we need is for the Member States to run compatible medical IT systems. This, of course, is where the Commission comes in and we expect it to take positive action on this issue."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph